<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303679</url>
  </required_header>
  <id_info>
    <org_study_id>Arobase (GINECO-BR107)</org_study_id>
    <nct_id>NCT01303679</nct_id>
  </id_info>
  <brief_title>1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer</brief_title>
  <official_title>Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In first-line metastatic breast cancer, the bevacizumab-taxane to progression or toxicity, is
      currently the standard treatment. In patients expressing hormone receptors, it was shown that
      hormone therapy administered in maintenance after induction chemotherapy, could have a
      benefit regarding the progression-free survival. The investigators make the hypothesis that
      there would be interest to discontinue treatment with taxane after 4 months, and to begin
      hormone therapy while continuing maintenance bevacizumab.

      Exemestane was chosen because it has been shown potentially active in patients who progressed
      after letrozole, anastrozole or tamoxifen.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not reveal any significant difference between the 2 treatment arms
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary free survival</measure>
    <time_frame>24 months for recruitment and 18 months for follow up</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>First Line Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel-bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>exemestane-bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV, 80mg/m² at d1, d8, d15</description>
    <arm_group_label>paclitaxel-bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks</description>
    <arm_group_label>paclitaxel-bevacizumab</arm_group_label>
    <arm_group_label>exemestane-bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>daily 25 mg (1 pill) oral intake</description>
    <arm_group_label>exemestane-bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 ans.

          -  Metastatic breast cancer or locally advanced

          -  RE+, HER2-

          -  Patient receiving paclitaxel-bevacizumab first line chemotherapy

        Exclusion Criteria:

          -  Previous treatment by exemestane (both in adjuvant or metastatic treatment).

          -  1st line of chemotherapy different thaan paclitaxel-bevacizumab.

          -  Treatment by paclitaxel-bevacizumab &gt; 18 weeks.

          -  HER2 positifs et/ou récepteurs aux oestrogènes négatifs.

          -  Previous thrombosis event within the 6 months before inclusion .

          -  Previous significant surgery within the 28 days before treatment start

          -  Previuous coagulopathy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas BACHELOT, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>GINECO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BACHELOT</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First line metastatic breast cancer</keyword>
  <keyword>Positive estrogen receptors</keyword>
  <keyword>Negative HER2 receptors</keyword>
  <keyword>At least stable disease after 4 months of paclitaxel-bevcizumab induction chemotheray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Taxane</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

